Multiple Myeloma

FDA sets November review date for J&J’s multiple myeloma CAR-T cilta-cel
Pharmaforum
Thu, 05/27/21 - 11:59 pm
JNJ
FDA
Multiple Myeloma
CAR-T
cilta-cel
Straight after its first cancer bispecific OK, J&J highlights two more at ASCO
Pharmaforum
Tue, 05/25/21 - 10:59 am
JNJ
ASCO 2021
talquetamab
teclistamab
Genmab
Janssen
Multiple Myeloma
AstraZeneca drops BCMA drug after seeing early clinical data
Fierce Biotech
Fri, 04/30/21 - 10:35 am
AstraZeneca
antibody-drug conjugate
MEDI2228
Multiple Myeloma
New CAR-T therapy from Bristol, Bluebird effective but too costly, ICER finds
BioPharma Dive
Tue, 04/6/21 - 11:00 pm
Bristol Myers Squibb
Bluebird Bio
ICER
Multiple Myeloma
CAR-T
Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma
Endpoints
Thu, 04/1/21 - 10:53 am
Sanofi
JNJ
Sarclisa
Kyprolis
Multiple Myeloma
FDA approves first CAR-T cell therapy for multiple myeloma
BioPharma Dive
Mon, 03/29/21 - 10:56 pm
Bristol-Myers Squibb
Bluebird Bio
CAR-T
Multiple Myeloma
Abecma
FDA
3 FDA Dates Biotech Investors Should Circle in 2021
Motley Fool
Sat, 12/26/20 - 08:27 pm
FDA
biotech
Bluebird Bio
ide-cel
Multiple Myeloma
Biogen
aducanumab
Alzheimer's disease
targeted therapeutics
umbralisib
maringal zone lymphoma
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA
Pharmaforum
Tue, 12/22/20 - 10:41 am
JNJ
Janssen
Multiple Myeloma
CAR-T
cilta-cel
FDA
Bristol-Myers Squibb
ide-cel
ASH: J&J links subcut BCMA bispecific to 73% response rate, plots aggressive investment
Fierce Biotech
Sun, 12/6/20 - 07:10 pm
ASH2020
JNJ
bispecifics
Multiple Myeloma
teclistamab
#ASH20: In a multiple myeloma showdown, Regeneron marches out new PhI data for its BCMA bispecific
Endpoints
Sat, 12/5/20 - 11:34 pm
ASH2020
Regeneron
Multiple Myeloma
clinical trials
REGN5458
FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial
Endpoints
Wed, 11/18/20 - 11:03 am
Cellectis
FDA
patient deaths
CAR-T
clinical trials
Multiple Myeloma
Janssen combines Darzalex with COVID-19 drug in new multiple myeloma submission
Pharmaforum
Fri, 11/13/20 - 12:11 pm
Janssen
Multiple Myeloma
Darzalex
EMA
FDA
J&J's Darzalex Proves Effective in Yet Another Multiple Myeloma Indication
BioSpace
Thu, 10/22/20 - 11:01 pm
JNJ
Genmab
clinical trials
Darzalex
Multiple Myeloma
Genmab and Janssen Head to Arbitration Table Over Darzalex Royalties
BioSpace
Wed, 09/23/20 - 10:22 am
Genmab
JNJ
Janssen
Darzalex
arbitration
Multiple Myeloma
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Motley Fool
Thu, 09/17/20 - 11:09 pm
Bristol-Myers Squibb
Dr Reddy's
Revlimid
Multiple Myeloma
J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in
Endpoints
Fri, 08/21/20 - 12:32 pm
JNJ
Darzalex
FDA
Multiple Myeloma
FDA approves GSK's BCMA drug, marking a rocky return to cancer for the British giant
Endpoints
Wed, 08/5/20 - 11:24 pm
GSK
FDA
Multiple Myeloma
belantamab mafodotin
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
BioPharma Dive
Thu, 07/30/20 - 12:01 am
Bristol-Myers Squibb
Bluebird Bio
FDA
ide-cel
cell therapy
Multiple Myeloma
FDA AdCom votes unanimously in favor of GSK myeloma drug, despite earlier agency skepticism
MedCity News
Tue, 07/14/20 - 11:22 pm
GSK
Multiple Myeloma
FDA
belantamab mafodotin
advisory panel
5 FDA approval decisions to watch in the 3rd quarter
BioPharma Dive
Thu, 07/9/20 - 11:09 am
FDA
Gilead Sciences
filgotinib
rheumatoid arthritis
GSK
belantamab mafodotin
Multiple Myeloma
NS Pharma
viltolarsen
Duchenne Muscular Dystrophy

Pages